Current management of gout in patients unresponsive or allergic to allopurinol

Joint Bone Spine

Volumn 71, Issue 6, 2004, Pages 481-485

  Bardin, Thomas ^a  

^a 2 R Ambroise Par 75010 Cedex P   (France)

Author keywords

Allopurinol; Gout; Hypersensibility

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMLODIPINE; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BENZBROMARONE; CYCLOSPORIN; FEBUXOSTAT; FENOFIBRATE; FUROSEMIDE; HEPARIN; LOSARTAN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PENICILLIN G; PHENYLPYRAZOLE Y 100; PROBENECID; RASBURICASE; TACROLIMUS; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; URATE OXIDASE; URICOSURIC AGENT; VIDARABINE; XANTHINE OXIDASE INHIBITOR;

ARTICLE; CONFUSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPEPSIA; GOUT; GUILLAIN BARRE SYNDROME; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYPERTENSION; HYPERURICEMIA; LEUKOPENIA; NEPHROTIC SYNDROME; PERIPHERAL NEUROPATHY; PRURITUS; RASH; SIDE EFFECT; SKIN MANIFESTATION; STONE FORMATION; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREMOR;

ALLOPURINOL; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; GOUT; GOUT SUPPRESSANTS; HUMANS;

EID: 10344228746     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2004.07.006     Document Type: Article

References (36)

1. E. Arromdee, C.J. Michet, C.S. Crowson, W.M. O'Fallon, and S.E. Gabriel Epidemiology of gout: is the incidence rising? J. Rheumatol. 29 2002 2403 2406
2. R.A. Terkeltaub Clinical practice Gout N. Engl. J. Med. 349 2003 1647 1655
3. F. Liot́, and C. Van:Reth Les manifestations d'intoĺrance ̀ l'allopurinol en 1996 M.F. Kahn D. Kuntz A. Dryll O. Meyer T. Bardin C. Gúrin L'Actualit́ Rhumatologique 1996 1996 Expansion Scientifique Fraņaise Paris 328 337
4. J. Benito-Leon, and J. Porta-Etessam Guillain-Barre syndrome and allopurinol-induced hypersensitivity Eur. Neurol. 45 2001 186 187
5. K.R. Hande, R.M. Noone, and W.J. Stone Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency Am. J. Med. 76 1984 47 56
6. J. Vazquez-Mellado, E.M. Morales, C. Pacheco-Tena, and R. Burgos-Vargas Relation between adverse events associated with allopurinol and renal function in patients with gout Ann. Rheum. Dis. 60 2001 981 983
7. F.C.M. Perez-Ruiz, M. Calabozo, M.J. Ferandez-Lopez, A. Herrero-Beites, E. Ruiz-Lucea, and G. Garcia-Erauskin Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study J. Clin. Rheumatol. 5 1999 49 55
8. H.K. Choi, K. Atkinson, E.W. Karlson, W. Willett, and G. Curhan Alcohol intake and risk of incident gout in men: a prospective study Lancet 363 2004 1277 1281
9. A.G. Fam Gout, diet, and the insulin resistance syndrome J. Rheumatol. 29 2002 1350 1355
10. H.K. Choi, K. Atkinson, E.W. Karlson, W. Willett, and G. Curhan Purine-rich foods, dairy and protein intake, and the risk of gout in men N. Engl. J. Med. 350 2004 1093 1103
11. T. Bardin Fenofibrate and losartan Ann. Rheum. Dis. 62 2003 497 498
12. A.L. Hepburn, S.A. Kaye, and M.D. Feher Long-term remission from gout associated with fenofibrate therapy Clin. Rheumatol. 22 2003 73 76
13. A.B. Gutman Uricosuric drugs, with special reference to probenecid and sulfinpyrazone Adv. Pharmacol. 4 1966 91 142
14. A. Ryckewaert, D. Kuntz, and F. Liot́ La goutte 1962 Welcome Issy l̀s Moulineaux
15. J.H. Talbott, and K.L. Terplan The kidney in gout Medicine (Baltimore) 39 1960 405 467
16. P. Insel Analgesic-antipyretic and antiinflammatory agents, and drugs employed in the treatment of gout J.G. Hardman A.G. Goodman L. Limbird Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed 1996 McGraw-Hill New York
17. M. Harris, L.R. Bryant, P. Danaher, and J. Alloway Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis J. Rheumatol. 27 2000 2873 2876
18. F. Perez-Ruiz, A. Alonso-Ruiz, M. Calabozo, A. Herrero-Beites, G. Garcia-Erauskin, and E. Ruiz-Lucea Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout Ann. Rheum. Dis. 57 1998 545 549
19. D.S. Sinclair, and I.H. Fox The pharmacology of hypouricemic effect of benzbromarone J. Rheumatol. 2 1975 437 445
20. I.H. Fox, and D.S. Sinclair The pharmacology of the hypouricemic effect of benzbromarone Adv. Exp. Med. Biol. 76B 1977 328 333
21. M. Arai, O. Yokosuka, K. Fujiwara, H. Kojima, T. Kanda, and H. Hirasawa Fulminant hepatic failure associated with benzbromarone treatment: a case report J. Gastroenterol Hepatol. 17 2002 625 626
22. O. Lockard Jr., C. Harmon, K. Nolph, and W. Irvin Allergic reaction to allopurinol with cross-reactivity to oxypurinol Ann. Intern. Med. 85 1976 333 335
23. A.G. Fam, J. Lewtas, J. Stein, and T.W. Paton Desensitization to allopurinol in patients with gout and cutaneous reactions Am. J. Med. 93 1992 299 302
24. A.G. Fam, S.M. Dunne, J. Iazzetta, and T.W. Paton Efficacy and safety of desensitization to allopurinol following cutaneous reactions Arthritis Rheum. 44 2001 231 238
25. J. Unsworth, D.R. Blake, A.E. D'Assis:Fonseca, and D.T. Beswick Desensitisation to allopurinol: a cautionary tale Ann. Rheum. Dis. 46 1987 646
26. S.B. Tanna, J.F. Barnes, and S.K. Seth Desensitization to allopurinol in a patient with previous failed desensitization Ann. Pharmacother. 33 1999 1180 1183
27. J.S. Bomalaski, and M.A. Clark Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase Curr. Rheumatol. Rep. 6 2004 240 247
28. S. Rozenberg, B. Roche, R. Dorent, A.C. Koeger, C. Borget, and N. Wrona Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases Rev. Rhum. Engl. Ed 62 1995 392 394
29. C.H. Pui, M.V. Relling, F. Lascombes, P.L. Harrison, A. Struxiano, and J.M. Mondesir Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies Leukemia 11 1997 1813 1816
30. R.C. Ribeiro, and C.H. Pui Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies Clin. Lymphoma. 3 2003 225 232
31. B.T. Yim, R.P. Sims-McCallum, and P.H. Chong Rasburicase for the treatment and prevention of hyperuricemia Ann. Pharmacother 37 2003 1047 1054
32. F. Perez-Ruiz, P. Gomez-Ullate, J.J. Amenabar, S. Zarraga, M. Calabozo, and A.M. Herrero-Beites Long-term efficacy of hyperuricaemia treatment in renal transplant patients Nephrol. Dial. Transplant. 18 2003 603 606
33. R.M. Zurcher, H.A. Bock, and G. Thiel Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study Nephrol. Dial. Transplant. 9 1994 548 551
34. J. Chanard, O. Toupance, S. Lavaud, B. Hurault de Ligny, C. Bernaud, and B. Moulin Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients Nephrol. Dial. Transplant. 18 2003 2147 2153
35. H.J. Schlitt, A. Barkmann, K.H. Boker, H.H. Schmidt, N. Emmanouilidis, and J. Rosenau Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study Lancet 357 2001 587 591
36. F. Jacobs, M.F. Mamzer-Bruneel, H. Skhiri, E. Thervet, C. Legendre, and H. Kreis Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout Transplantation 64 1997 1087 1088